market-trends is the sole category represented across all 1 tracked stories. Charles River Laboratories is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each carries 3 original sources on average. We currently track 1 Healthcare story that mention IQVIA Holdings, all published on June 19, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about IQVIA Holdings
market-trends is the sole category represented across all 1 tracked stories. Charles River Laboratories is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each carries 3 original sources on average. We currently track 1 Healthcare story that mention IQVIA Holdings, all published on June 19, 2026.
Stories tracked
1
Sources per story
3
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 2 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering IQVIA Holdings. Shared-story counts are live from our verified record — not editorial picks.
Morgan Stanley’s upgrade of Charles River and downgrade of IQVIA signal a shift in healthcare R&D outsourcing. CROs with deep ties to small biotech stands to gain as venture funding rebounds, potentially accelerating drug development timelines and altering cost structures for health systems.
IQVIA Holdings is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.